Call for Concept Proposals for 2023 NIH CFAR Ending the HIV Epidemic Supplement-Funded Research Projects

Call for Concept Proposals for 2023 NIH CFAR Ending the HIV Epidemic Supplement-Funded Research Projects

NOTICE OF SPECIAL INTEREST (NOSI): 2023 NIH CFAR Ending the HIV Epidemic Supplements 

The Center for AIDS Research (CFAR) at Emory University is soliciting concept proposals for supplemental grant applications in response to the 2023 NIH CFAR Ending the HIV Epidemic Funding Opportunity. CFAR Ending the HIV Epidemic (EHE) Supplements are up to $150,000 (direct cost) per year for up to two years. Proposals must be in response to one of the following four topics:

EHE Scientific Topics for 2023:

1. Syndemic Approaches to HIV Prevention, Treatment or Care:

  • using syndemic theory and approaches to (a) increase focus on intersecting diseases and social conditions that exacerbate health inequities, and (b) enhance the evidence base for effective successful approaches to assess, monitor, and intervene with respect to these intersections for optimal outcomes in HIV prevention or treatment

2. Leveraging Pharmacies to Advance HIV Testing, Prevention, and Care:

  • research projects designed to further capacitate, field, and scale the routine delivery of HIV testing, prevention, and care services through pharmacists and pharmacy settings in the U.S.

3. Strategies to Improve Linkage to HIV Care and Services Post-Incarceration:

  • improving linkage and connection to mental health, substance use, social services, housing, job services, HIV care, and any other community resources post-incarceration; The goals are to optimize timely linkage to HIV care, retention, and viral suppression among people living with HIV (PLWH) re-entering their communities.

4. Cluster Detection and Response Strategies:

  • using cluster detection and response strategies to address identified service gaps, reduce HIV-related health disparities, and contain outbreaks

MORE INFORMATION ON THESE TOPICS CAN BE FOUND IN THE NIH CFAR NOSI LINKED AT THE BOTTOM OF THIS PAGE.

Applicants must meet the following eligibility criteria.

ELIGIBILITY:

  • Faculty or faculty-equivalent position with a full-time appointment at Emory University as of award start date (anticipated June 1, 2023);
  • And, eligibility to be PI on an NIH R-level grant

IMPLEMENTING PARTNER REQUIREMENT:

Applicants must collaborate with an implementing partner(s) located in one of 57 priority jurisdictions for EHE.  Implementing partners can include community, local, county and state health departments, community-based organizations, and clinics receiving funds from the CDC, HRSA, SAMHSA, or IHS.  NIH CFAR EHE Supplement reserach projects should be developed by a team of CFAR investigators, community partners, implementing partners, and people with lived experience to support the local ending the HIV epidemic plans.

DEADLINE FOR SUBMISSION: February 3, 2023 by MIDNIGHT EST

APPLICATION PROCESS

Interested applicants must complete THIS ONLINE FORM to submit their one-page concept proposals as a single PDF document by midnight EST on Friday, February 3, 2023.

Concept proposal PDFs must include the following:

1. brief scientific rationale

2. proposed specific aims

3. relevance to the CFAR EHE Supplement scientific topic selected (see 1-4 above)

4. proposal’s potential to impact local EHE efforts

The CFAR Leadership will review submitted applications to select those which will be invited to submit a full application to NIH. A member of the Emory CFAR Administrative Core will contact all applicants by February 10th regarding the review outcome and to support those who were seelected to move forward in the appication process.

Please contact Shelle Bryant (sbryant@emory.edu) with any questions regarding this process.

Emory CFAR Members Receive R01 from NIH NIDCR to Accelerate Search for Novel Biomarkers for Oral HPV Infection Among People Living with HIV

Emory CFAR Members Receive R01 from NIH NIDCR to Accelerate Search for Novel Biomarkers for Oral HPV Infection Among People Living with HIV

Emory University is awarded 3.9 million ($3,930,416 from 2022 to 2027) from the National Institutes of Health (NIH, NIDCR) for a new R01 to accelerate the search for novel biomarkers for oral human papillomavirus (HPV) infection among people living with HIV. The principal investigators, Canhua Xiao, PhD, RN, FAAN is an Associate professor in the School of Nursing, and Lisa Flowers, MD, MPH is a Professor in the Department of Obstetrics and Gynecology, Emory University School of Medicine.

HPV infection has been identified as a definite human carcinogen for oropharyngeal cancer.  People living with HIV (PLWH) have a much higher rate of oral HPV infection and oropharyngeal cancer than the general population.  Yet, the etiology and pathophysiology of oral HPV infection in PWH are not well-documented. Therefore, the collaboratory team will examine the associations among oral microbiome, periodontal diseases, and oral HPV infection.  In addition, the team to identify and harness the unique immunological underpinnings of oral HPV infection in people with HIV.  The immunological analysis of this study will be conducted by the study Co-investigator Vijayakumar Velu, PhD an immunologist, Assistant Professor from Emory Vaccine Center and Emory National Primate Center. Other Co-investigators are Drs. David Reznik, Deborah Bruner, Sudeshna Paul, Timonthy D. Read, Minh Ly T. Nguyen, Terryl Hartman, Elizabeth Unger, and Gypsyamber D’Souza.  The findings may indicate new biomarkers and novel therapeutic targets for preventing and managing oral HPV infection.

 

The study leaders are (left to right) Canhua Xiao, PhD, RN, FAAN; Lisa Flowers, MD, MPH; and Vijayakumar Velu, PhD.

Call for Proposals that Address the Intersection of HIV and the Monkeypox Virus

Call for Proposals that Address the Intersection of HIV and the Monkeypox Virus

NOTICE OF SPECIAL INTEREST (NOSI): 2023 NIH CFAR Ending the HIV Epidemic Supplements 

The Center for AIDS Research (CFAR) at Emory University is soliciting concept proposals for supplemental grant applications in response to the 2023 NIH CFAR Ending the HIV Epidemic Funding Opportunity. CFAR Ending the HIV Epidemic (EHE) Supplements are up to $150,000 (direct cost) per year for up to two years. Proposals must be in response to one of the following four topics:

EHE Scientific Topics for 2023:

  1. Syndemic Approaches to HIV Prevention, Treatment or Care:
    • using syndemic theory and approaches to (a) increase focus on intersecting diseases and social conditions that exacerbate health inequities, and (b) enhance the evidence base for effective successful approaches to assess, monitor, and intervene with respect to these intersections for optimal outcomes in HIV prevention or treatment
  2. Leveraging Pharmacies to Advance HIV Testing, Prevention, and Care:
    • research projects designed to further capacitate, field, and scale the routine delivery of HIV testing, prevention, and care services through pharmacists and pharmacy settings in the U.S.
  3. Strategies to Improve Linkage to HIV Care and Services Post-Incarceration:
    • improving linkage and connection to mental health, substance use, social services, housing, job services, HIV care, and any other community resources post-incarceration; The goals are to optimize timely linkage to HIV care, retention, and viral suppression among people living with HIV (PLWH) re-entering their communities.
  4. Cluster Detection and Response Strategies:
    • using cluster detection and response strategies to address identified service gaps, reduce HIV-related health disparities, and contain outbreaks

MORE INFORMATION ON THESE TOPICS CAN BE FOUND IN THE NIH CFAR NOSI LINKED AT THE BOTTOM OF THIS PAGE.

Applicants must be current Emory faculty or faculty-equivalent who meet the following eligibility criteria.

ELIGIBILITY:

  • Eligibility to be PI on an NIH R-level grant
  • Faculty or faculty-equivalent position with a full-time appointment at Emory University as of award start date (anticipated June 1, 2023).
  • Meets the definition of an NIH “New Investigator” in HIV/AIDS. Specifically, prior funding as an NIH independent investigator makes an applicant ineligible ONLY IF the funding has been in the HIV field.
    • Exception: Investigators with prior independent NIH funding in HIV are eligible if they have not been the PI on any NIH HIV-related grant within the last five years.

DEADLINE FOR SUBMISSION: February 3, 2023 by MIDNIGHT EST

APPLICATION PROCESS

Interesetd applicants must complete THIS ONLINE FORM to submit their one-page concept proposals as a single PDF document by midnight EST on Friday, February 3, 2023.

Concept proposal PDFs must include the following:

  1. brief scientific rationale
  2. proposed specific aims
  3. relevance to the CFAR EHE Supplement topic selected (see 1-4 above)
  4. proposal’s potential to impact local EHE efforts

The CFAR Leadership will review submitted applications to select those which will be invited to submit a full application to NIH. A member of the Emory CFAR Administrative Core will contact all applicants by February 10th regarding the review outcome and to support those who were seelected to move forward in the appication process.

Please contact Shelle Bryant (sbryant@emory.edu) with any questions regarding this process.

Call for Applications for the Emory Training Program in HIV Translational Research to End the Epidemic

Call for Applications for the Emory Training Program in HIV Translational Research to End the Epidemic

TRAINING OPPORTUNITY: Fellow-driven & mentor-supported HIV translational research fellowships at Emory University

Are you a PhD, MD, MD/PhD graduate with an interest in HIV Translational Research? Are you within seven years of your terminal degree? Are you a U.S. Citizen or Naturalized (Green Card) U.S. Citizen? Can you devote two years to training?

All trainees must commit full-time effort to the program and its related research activities.

Eligible Areas of HIV Research

  • Laboratory-based science, vaccine, and cure research
  • Patient-centered clinical research
  • Public health and implementation science

Trainees will gain expertise in cross-cutting areas ofscience and translation to the Ending the HIV Epidemic Initiative

HIV T32 Program Trainees will Receive:

  • Annual stipend at appropriate NIH-specifiedlevel based on years of postdoc experience
  • Travel & childcare allotments; research supplies
  • Tuition support for formal didactic training intranslational research (MSCR, CPTR, or selectedgraduate level courses)
  • Hands-on translational research rotation

DEADLINE FOR SUBMISSION: April 15, 2022

Application Process:

1. Potential candidates should complete an HIV T32 Interest Form to initiate discussion with the faculty Program Director (PD) in the target area of interest regarding the candidate application: https://bit.ly/EmoryHIVT32

a. Laboratory-based basic science, vaccine, and cure research: Ann Chahroudi, MD, PhD
b. Patient-centered clinical research: Colleen Kelley, MD, MPH
c. Public health and implementation science: Patrick Sullivan, DVM, PhD

2. Applicants will identify potential mentor(s) from the list below during the discussion with the faculty PD. The PD will then contact the mentor(s) suggested to confirm willingness to meet with the applicant.

3.  The Program Coordinator will then connect applicants and potential mentors. It is up to the applicant/mentor to meet and mutually decide the best fit. Once the mentor has agreed to support the trainee throughout the duration of the appointment, the applicant must notify the Program Coordinator via email of final decision.

4.  Approval to apply should be obtained prior to April 1, 2022. Candidates are encouraged to apply after mentor and program reviews are

To apply, submit an application package including the following documents as a single PDF via email to deaunna.thomas@emory.edu by 5 PM EST on April 15, 2022:

  • Cover letter specifying focus area of interest with statement of future goals for a career in HIV research. Applicants should include personal qualifications for the fellowship and what they hope to gain from the fellowship;
  • Current CV or NIH biosketch;
  • A letter of support from the proposed HIV T32 mentor;
  • Letter(s) of support from one other scientist (e.g. recent supervisor, mentor, or a collaborator);
  • A two-page description of the proposed research project and proposed didactic training plan (including graphs/figures but not references);
  • MD applicants from clinical departments must also provide a letter from the applicant’s Department/Division Chair, indicating departmental commitment to provide at least 75% protected time for the trainee applicant to devote to the proposed research project. This letter can be same as the required letter of support from one other scientist, described above.
Emory CFAR at Virtual CROI 2022

Emory CFAR at Virtual CROI 2022

Strong Showing by Emory University at CROI 2022

Emory University is well-represented at the Virtual CROI 2022 conference with 33 presentations — 8 talks (two of which are invited) and 25 posters — featuring Emory faculty, students, and staff.  Please use the spreadsheet below as guides to support your fellow Emory CFAR Members by tuning in for their sessions and Q&A.  We also invite you to follow along with us on Twitter (@EmoryCFAR) for daily tweets featuring Emory CFAR Member presentations!

We are pleased to highlight 10 Emory CFAR Members who received prestigious New Investigator Scholarships this year.  Join us in congratulating:

  1. Brady Bennett
  2. Sakthivel Govindaraj
  3. Timothy Hoang
  4. Christina Mallarino-Haeger
  5. Aditi Ramakrishnan
  6. Maura Statzu
  7. Boghuma Titanji
  8. Vanessa Van Doren
  9. Elise Viox
  10. Bhrugu Yagnik

On behalf of the Emory CFAR, congratulations to all of you who are representing Emory at virtual #CROI2022!

CFAR at Emory Newly Established Scientific Working Groups Leadership Announcement

CFAR at Emory Newly Established Scientific Working Groups Leadership Announcement

Health Equity Scientific Working Group

The central purpose of the Health Equity Scientific Working Group (SWG) is to expand NIH-funded community-engaged research to promote health equity at Emory in collaboration with Morehouse School of Medicine (SOM) and community stakeholders in the Atlanta area. Activities will include hosting research proposal feedback sessions, quarterly seminars, networking events, and/or career development sessions as opportunities for CFAR Members, Morehouse faculty, and community partners to interact; and pilot test several mentoring mechanisms focused on developing underrepresented minority investigators. 

Rhonda Conerly Holliday, PhD, MA
Co‐Director, Health Equity SWG
Dr. Holliday (Rhonda) is an Associate Professor of Community Health and Preventive Medicine at the Morehouse School of Medicine. She is a public health researcher with a background in developmental psychology. Rhonda has extensive expertise in Community Based Participatory Research (CPBR), health equity, and health communications. Her topical areas of interest include HIV prevention among adolescents and emerging adults, including college students and justice-involved individuals. She is the PI for the core research project for the Morehouse School of Medicine Prevention Research Center (U48DP006411), focusing on implementing a CBPR approach to HIV prevention on the campuses of HBCUs and Minority Serving Institutions. Importantly for this SWG, she has published not only on the results of her CBPR projects, but also on the methods and lessons learned in developing and executing community-academic partnerships.

Sophia Hussen, MD, MPH
Co‐Director, Health Equity SWG
Dr. Hussen (Sophia) is an Associate Professor of Global Health in the Rollins School of Public Health at Emory University with a joint appointment in the Division of Infectious Diseases in the Emory University School of Medicine. Sophia is an infectious diseases physician and public health scientist who conducts research related to improving HIV and mental health outcomes for youth living with HIV, with a particular focus on young Black gay and bisexual men. She has recently completed a CDC-funded pilot trial of a CBPR-developed intervention to enhance social capital among young Black gay and bisexual men living with HIV, and she is also incorporating participatory methodologies into ongoing NIH-funded intervention development grants (R34MH124638; R34 MH116805) and exploratory mixed methods work (R21MH121164). Sophia also leads community engagement efforts within the Emory Clinical Trials Unit (CTU) and the Atlanta site of the MACS/WIHS CCS.

Alphonso Mills, BA
Co‐Director, Health Equity SWG
Mr. Mills (Alphonso) is a community health worker at Positive Impact Health Centers (PIHC), a large Atlanta community-based organization focusing on infectious diseases care, mental health care, substance use treatment, and other support services for people living with and at risk for HIV. Alphonso, who is openly living with HIV, has developed a strong track record of both professional and personal advocacy in the local Atlanta community. He is a 2020 graduate of Morehouse College, where he majored in psychology. He has also served on a Community Advisory Board for several of Dr. Hussen’s research projects since 2017. Due to the sum of his professional, research-related, and personal experiences over the last five years, Alphonso has extensive community connections with key organizations and individuals working in the HIV field in Atlanta. He also has experience with CBPR and other research as a participant, research assistant, and advisor.

Next Generation Therapeutics Scientific Working Group

The Next Generation Therapeutics Scientific Working Group (SWG) seeks to catalyze opportunities for team science within and across Emory CFAR institutions to set the foundation for future exploration and development of (i) novel approaches for viral suppression in people living with HIV using combinations of therapeutics that overcome drug resistance associated with current ART and are delivered as formulations designed to facilitate their long-term release; and (ii) immune-based strategies, focusing on those FDA-approved for other diseases, aimed at targeting and limiting HIV residual disease and HIV reservoirs. Activities will include hosting research proposal feedback sessions, educational, networking events, and/or career development sessions as opportunities for CFAR Members, CDC staff, and Georgia Tech and Morehouse School of Medicine faculty to interact; provide structured mentoring for Early-Stage Investigators in the field to ensure a robust scientific future; and promote multi-investigator applications to the CFAR Developmental Core and ultimately to the NIH.

Stefan G. Sarafianos, PhD
Co‐Director, Next Generation Therapeutics SWG
Dr. Sarafianos (Stefan) is the Nahmias-Schinazi Chair, Professor, and Associate Director of the Laboratory of Biochemical Pharmacology (LOBP) Division in the Department of Pediatrics at Emory. He studies viral replication at the molecular level, its inhibition, drug resistance, and the development of drugs that will treat human disease by novel mechanisms of action. Stefan has worked in retroviral structural biology, biochemistry, and virology since 1993 and has published more than 170 manuscripts. In early biochemical work he identified the HIV reverse transcriptase (RT) active site residues that are involved in dNTP, DNA, and PPi binding prior to any crystallographic information. His lab has had extensive contributions in the development of potent inhibitors that act by novel mechanisms of action including EFdA (islatravir), currently in Phase III clinical trials (for which he was recently awarded an NIH MERIT award) and in characterizing their mechanisms of inhibition and resistance. Stefan has worked in the HIV capsid field for several years now, and his lab was the first to solve the elusive crystal structure of the native (uncrosslinked) hexameric HIV capsid protein (CA) in apo form and in complex with CA-targeting antiviral PF74 (Science, 2015). This set of structures provided the framework for studies in which 45 crystal structures of the native CA hexamer were solved with mutations that affect capsid stability, and in complexes with host factor peptides and CA-targeting antivirals. Extensive biophysical and virological characterization revealed compounds with proprietary compounds that improved potency, resistance profiles, and metabolic stability compared to PF74. Some compounds can inhibit clinically-relevant PF74- and GS-6207-resistant HIV-1 strains.

Mirko Paiardini, PhD
Co-Director, Next Generation Therapeutics SWG
Dr. Paiardini (Mirko) is an Associate Professor of Pathology and Laboratory Medicine at Emory and a Researcher at Yerkes National Primate Research Center and the Emory Vaccine Center. For almost 20 years, Mirko has been involved in studies of AIDS pathogenesis in both HIV-infected individuals and in the models of SIV infection in rhesus macaques (RMs). Mirko gained extensive experience with in vivo studies of SIV infection of RMs in which virus replication is suppressed by a potent ART regimen, thus validating this model for studies of HIV cure. He led several studies in which in vivo immune interventions have been conducted in ART-suppressed SIV-infected RMs, aimed at reducing, and possibly eliminating, immune dysfunctions and HIV persistence in people living with HIV, including treatment with IL-21, IL-15 agonist, fingolimod, as well as blockade of PD-1, CTLA-4, and IL-10. More recently, his laboratory developed the NHP model of SARS-CoV-2 infection to test the therapeutic potential of baricitinib. He directs several NIH-funded studies of HIV immunology, pathogenesis, and persistence. He is the principal investigator of ERASE (Enterprise for Research and Advocacy to Stop and Eradicate) HIV, which is an NIH-funded international collaboratory aimed at developing therapeutic interventions to cure HIV infection.

Susan Pereira Ribeiro, PhD
Associate Director, Next Generation Therapeutics SWG
Dr. Ribeiro (Susan) is an Assistant Professor of Translational Medicine in the Department of Pathology at Emory University. She is an immunologist with experience in multi-omics approaches and with expertise in the development of cellular and immune assays and sophisticated flow cytometry models. Susan has focused in pathogenesis, progression and responses to immune therapy in order to discriminate mechanisms that leads to different outcomes in different individuals (Ex. Responders and Non-responders to immune therapy). She has experience with the cellular and molecular aspects of HIV immune pathogenesis and immunotherapies, focused on HIV reservoir evaluation, immune-phenotyping, and also vaccine development/response assessment, and in vitro efficacy of HIV-CAR T cells. Most recently her research has focused on understanding the mechanisms of HIV reservoir maintenance and the absence of CD4 T cell recovery in HIV infected subjects that show different clinical outcomes .

James Kohler, PhD
Associate Director, Next Generation Therapeutics SWG
Dr. Kohler (James) is an Assistant Professor Laboratory of Biochemical Pharmacology Division in the Department of Pediatrics at Emory. James has expertise in mucosal immunology, mouse transgenic models, pathogenesis (cardiac and renal) and toxicity models for HIV and antiviral therapies for human viral infections. His past training and research experience have included development and use of murine models to measure induction of mucosal immunity, signal transduction pathways associated in immune targets of HIV-1, tissue-specific antiretroviral toxicity, and HIV-1 cell-tropism and mutagenesis. James provides mentorship and co-leads the HIV Division of the Laboratory of Biochemical Pharmacology (Schinazi Lab). He previously served as Associate Director of the Emory CFAR HIV Cure SWG, now the HIV Cure Research Cluster.